PUBLISHER: IMARC | PRODUCT CODE: 1422888
PUBLISHER: IMARC | PRODUCT CODE: 1422888
Minimal Residual Disease Testing Market by Technology (Flow Cytometry, Polymerase Chain Reaction, Next Generation Sequencing, and Others), Application, End User, and Region 2024-2032
Abstract
The global minimal residual disease (MRD) testing market size reached US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.1 Billion by 2032, exhibiting a growth rate (CAGR) of 10.21% during 2024-2032. Significant growth in the healthcare industry, extensive research and development (R&D) activities and rapid technological advancements represent some of the key factors driving the market.
Minimal residual disease (MRD) testing is a medical test used to detect and monitor small amounts of cancer cells that may remain in a patient's body after undergoing cancer treatment. It is widely used to test a variety of different types of cancer, such as leukemia, lymphoma, multiple myeloma, and some solid tumors. MRD testing uses highly sensitive methods, including cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS). It is an important medical test for monitoring cancer patients and helping doctors to make more informed treatment decisions. MRD testing helps in the early detection of disease recurrence, providing a more accurate assessment of treatment response and guiding personalized treatment planning by identifying patients, improving patient outcomes, and enhancing customized treatment planning.
Minimal Residual Disease (MRD) Testing Market Trends:
The increasing prevalence of cancer across the globe is one of the key factors driving the market growth. MRD testing is a highly sensitive technique that is widely used to detect residual cancer cells, which helps in an early indication of disease recurrence and helps guide personalized treatment planning. In line with this, the widespread adoption of MRD testing as a diagnostic and monitoring tool in hematological cancers that begin in blood-forming tissues or the cell of the immune system is favoring the market growth. Moreover, the shifting consumer preference toward personalized medicine that allows customized treatment planning and monitoring are acting as another growth-inducing factor. Apart from this, the integration of artificial intelligence (AI) with MRD testing that helps to identify patterns, predict the likelihood of recurrence, improve the accuracy and effectiveness of diagnosis, and help clinicians to make more informed decisions about patient care, is providing an impetus to the market growth. Additionally, the increasing adoption of NGS technology to determine the sequence of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) to study the genetic variations associated with the disease is creating a positive outlook for the market. Furthermore, growing awareness among people about the importance of identifying the presence of carcinogenic substances that can cause cancer in the body is propelling the market growth. Other factors, including significant growth in the healthcare industry, extensive research and development (R&D) activities, and increasing investments in the field of MRD testing programs, are anticipated to drive the market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global minimal residual disease (MRD) testing market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on technology, application, and end user.
Technology Insights:
Flow Cytometry
Polymerase Chain Reaction (PCR)
Next Generation Sequencing (NGS)
Others
The report has provided a detailed breakup and analysis of the minimal residual disease (MRD) testing market based on the technology. This includes flow cytometry, polymerase chain reaction (PCR), next generation sequencing (NGS) and others. According to the report, polymerase chain reaction (PCR) represented the largest segment.
Application Insights:
Hematological Malignancy
Leukemia
Lymphoma
Solid Tumors
A detailed breakup and analysis of the minimal residual disease (MRD) testing market based on the application has also been provided in the report. This includes hematological malignancy (leukemia and lymphoma) and solid tumors. According to the report, hematological malignancy (leukemia and lymphoma) accounted for the largest market share.
End User Insights:
Hospitals and Speciality Clinics
Diagnostic Laboratories
Academic and Research Institutes
Others
The report has provided a detailed breakup and analysis of the minimal residual disease (MRD) testing market based on the end user. This includes hospitals and speciality clinics, diagnostic laboratories, academic and research institutes, and others. According to the report, hospitals and speciality clinics represented the largest segment.
Regional Insights:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for minimal residual disease (MRD) testing. Some of the factors driving the North America minimal residual disease (MRD) testing market included the increasing prevalence of cancer, significant growth in the healthcare industry, and extensive research and development (R&D) activities.
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global minimal residual disease (MRD) testing market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Adaptive Biotechnologies Corporation, Arup Laboratories Inc., Bio-Rad Laboratories Inc., Guardant Health, Invivoscribe Inc., Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, etc.
Key Questions Answered in This Report:
- How has the global minimal residual disease (MRD) testing market performed so far, and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global minimal residual disease (MRD) testing market?
- What is the impact of each driver, restraint, and opportunity on the global minimal residual disease (MRD) testing market?
- What are the key regional markets?
- Which countries represent the most attractive minimal residual disease (MRD) testing market?
- What is the breakup of the market based on technology?
- Which is the most attractive technology in the minimal residual disease (MRD) testing market?
- What is the breakup of the market based on the application?
- Which is the most attractive application in the minimal residual disease (MRD) testing market?
- What is the breakup of the market based on the end user?
- Which is the most attractive end user in the minimal residual disease (MRD) testing market?
- What is the competitive structure of the global minimal residual disease (MRD) testing market?
- Who are the key players/companies in the global minimal residual disease (MRD) testing market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Minimal Residual Disease (MRD) Testing Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Technology
- 6.1 Flow Cytometry
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Polymerase Chain Reaction (PCR)
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Next Generation Sequencing (NGS)
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Others
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
7 Market Breakup by Application
- 7.1 Hematological Malignancy
- 7.1.1 Market Trends
- 7.1.2 Key Segments
- 7.1.2.1 Leukemia
- 7.1.2.2 Lymphoma
- 7.1.3 Market Forecast
- 7.2 Solid Tumors
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
8 Market Breakup by End User
- 8.1 Hospitals and Speciality Clinics
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Diagnostic Laboratories
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Academic and Research Institutes
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.1 United States
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.2.1 China
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.1 Germany
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.1 Brazil
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 Drivers, Restraints, and Opportunities
- 10.1 Overview
- 10.2 Drivers
- 10.3 Restraints
- 10.4 Opportunities
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Adaptive Biotechnologies Corporation
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.2 Arup Laboratories Inc.
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 SWOT Analysis
- 14.3.3 Bio-Rad Laboratories Inc.
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 Guardant Health
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.5 Invivoscribe Inc.
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.6 Natera Inc.
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.7 NeoGenomics Laboratories Inc.
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 Financials
- 14.3.8 Sysmex Corporation
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.1 Adaptive Biotechnologies Corporation
List of Figures
- Figure 1: Global: Minimal Residual Disease Testing Market: Major Drivers and Challenges
- Figure 2: Global: Minimal Residual Disease Testing Market: Sales Value (in Billion US$), 2018-2023
- Figure 3: Global: Minimal Residual Disease Testing Market Forecast: Sales Value (in Billion US$), 2024-2032
- Figure 4: Global: Minimal Residual Disease Testing Market: Breakup by Technology (in %), 2023
- Figure 5: Global: Minimal Residual Disease Testing Market: Breakup by Application (in %), 2023
- Figure 6: Global: Minimal Residual Disease Testing Market: Breakup by End User (in %), 2023
- Figure 7: Global: Minimal Residual Disease Testing Market: Breakup by Region (in %), 2023
- Figure 8: Global: Minimal Residual Disease Testing (Flow Cytometry) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 9: Global: Minimal Residual Disease Testing (Flow Cytometry) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 10: Global: Minimal Residual Disease Testing (Polymerase Chain Reaction (PCR)) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 11: Global: Minimal Residual Disease Testing (Polymerase Chain Reaction (PCR)) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 12: Global: Minimal Residual Disease Testing (Next Generation Sequencing (NGS)) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 13: Global: Minimal Residual Disease Testing (Next Generation Sequencing (NGS)) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 14: Global: Minimal Residual Disease Testing (Other Technologies) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 15: Global: Minimal Residual Disease Testing (Other Technologies) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 16: Global: Minimal Residual Disease Testing (Hematological Malignancy) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 17: Global: Minimal Residual Disease Testing (Hematological Malignancy) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 18: Global: Minimal Residual Disease Testing (Solid Tumors) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 19: Global: Minimal Residual Disease Testing (Solid Tumors) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 20: Global: Minimal Residual Disease Testing (Hospitals and Speciality Clinics) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 21: Global: Minimal Residual Disease Testing (Hospitals and Speciality Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 22: Global: Minimal Residual Disease Testing (Diagnostic Laboratories) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 23: Global: Minimal Residual Disease Testing (Diagnostic Laboratories) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 24: Global: Minimal Residual Disease Testing (Academic and Research Institutes) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 25: Global: Minimal Residual Disease Testing (Academic and Research Institutes) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 26: Global: Minimal Residual Disease Testing (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 27: Global: Minimal Residual Disease Testing (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 28: North America: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
- Figure 29: North America: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 30: United States: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
- Figure 31: United States: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 32: Canada: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
- Figure 33: Canada: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 34: Asia-Pacific: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
- Figure 35: Asia-Pacific: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 36: China: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
- Figure 37: China: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 38: Japan: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
- Figure 39: Japan: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 40: India: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
- Figure 41: India: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 42: South Korea: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
- Figure 43: South Korea: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 44: Australia: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
- Figure 45: Australia: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 46: Indonesia: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
- Figure 47: Indonesia: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 48: Others: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
- Figure 49: Others: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 50: Europe: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
- Figure 51: Europe: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 52: Germany: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
- Figure 53: Germany: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 54: France: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
- Figure 55: France: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 56: United Kingdom: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
- Figure 57: United Kingdom: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 58: Italy: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
- Figure 59: Italy: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 60: Spain: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
- Figure 61: Spain: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 62: Russia: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
- Figure 63: Russia: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 64: Others: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
- Figure 65: Others: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 66: Latin America: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
- Figure 67: Latin America: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 68: Brazil: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
- Figure 69: Brazil: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 70: Mexico: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
- Figure 71: Mexico: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 72: Others: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
- Figure 73: Others: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 74: Middle East and Africa: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
- Figure 75: Middle East and Africa: Minimal Residual Disease Testing Market: Breakup by Country (in %), 2023
- Figure 76: Middle East and Africa: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 77: Global: Minimal Residual Disease Testing Industry: Drivers, Restraints, and Opportunities
- Figure 78: Global: Minimal Residual Disease Testing Industry: Value Chain Analysis
- Figure 79: Global: Minimal Residual Disease Testing Industry: Porter's Five Forces Analysis
List of Tables
- Table 1: Global: Minimal Residual Disease Testing Market: Key Industry Highlights, 2023 & 2032
- Table 2: Global: Minimal Residual Disease Testing Market Forecast: Breakup by Technology (in Million US$), 2024-2032
- Table 3: Global: Minimal Residual Disease Testing Market Forecast: Breakup by Application (in Million US$), 2024-2032
- Table 4: Global: Minimal Residual Disease Testing Market Forecast: Breakup by End User (in Million US$), 2024-2032
- Table 5: Global: Minimal Residual Disease Testing Market Forecast: Breakup by Region (in Million US$), 2024-2032
- Table 6: Global: Minimal Residual Disease Testing Market: Competitive Structure
- Table 7: Global: Minimal Residual Disease Testing Market: Key Players
